NCT03171493 is a Phase 1 clinical trial of MV-NIS in Urothelial Carcinoma, sponsored by Vyriad, Inc..

Who is sponsoring NCT03171493?

NCT03171493 is sponsored by Vyriad, Inc..

What drugs are being tested in NCT03171493?

Interventions in NCT03171493: MV-NIS.

What condition does NCT03171493 study?

NCT03171493 studies Urothelial Carcinoma.

Is NCT03171493 still recruiting?

NCT03171493 is currently completed. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT03171493

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy

Completed Phase 1 Last updated 27 June 2023

What this trial tests

Phase 1 trial testing MV-NIS in Urothelial Carcinoma in 8 participants. Completed in 12 May 2023.

Timeline

20 July 2018

Primary endpoint
11 February 2021

12 May 2023

Quick facts

Lead sponsor	Vyriad, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	20 July 2018
Primary completion	11 February 2021
Estimated completion	12 May 2023
Sites	3 locations across United States

Drugs / interventions tested

MV-NIS — full drug profile →

Conditions studied

Urothelial Carcinoma — all drugs for Urothelial Carcinoma →

Sponsor

Vyriad, Inc. — full company profile →

Who can join

18 and older, any sex, with Urothelial Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1 study designed to test the tolerability and feasibility of intravesical therapy with an attenuated Measles virus (MV-NIS) in patients with urothelial carcinoma who are undergoing radical cystectomy but are ineligible or do not desire neoadjuvant chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Delivery and Biosafety of Oncolytic Virotherapy.
Li L, Liu S, Han D, Tang B, et al · · 2020 · cited 109× · PMID 32373515 · DOI 10.3389/fonc.2020.00475
Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies.
Liu X, Yin L, Shen S, Hou Y. · · 2023 · cited 75× · PMID 37013041 · DOI 10.1016/j.gendis.2021.09.006
Measles Virus as an Oncolytic Immunotherapy.
Engeland CE, Ungerechts G. · · 2021 · cited 66× · PMID 33535479 · DOI 10.3390/cancers13030544
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Pol JG, Lévesque S, Workenhe ST, Gujar S, et al · · 2018 · cited 61× · PMID 30524901 · DOI 10.1080/2162402x.2018.1503032
Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.
Yun CO, Hong J, Yoon AR. · · 2022 · cited 45× · PMID 36091031 · DOI 10.3389/fimmu.2022.953410
Cancer stem cells: a target for overcoming therapeutic resistance and relapse.
Zhang S, Yang R, Ouyang Y, Shen Y, et al · · 2024 · cited 20× · PMID 38164743 · DOI 10.20892/j.issn.2095-3941.2023.0333
The use of oncolytic virotherapy in the neoadjuvant setting.
Thomas RJ, Bartee E. · · 2022 · cited 20× · PMID 35414592 · DOI 10.1136/jitc-2021-004462
Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (<i>NIS</i>) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells.
Tutter M, Schug C, Schmohl KA, Urnauer S, et al · · 2020 · cited 17× · PMID 32292510 · DOI 10.7150/thno.41489

Verify or expand the search:

Other trials of MV-NIS

Trials testing the same drug.

NCT02919449 — Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab · Phase 1 · terminated

Other recruiting trials for Urothelial Carcinoma

Currently open trials in the same condition.

NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting

Other Vyriad, Inc. trials

Trials by the same sponsor.

NCT03647163 — Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tu · Phase 1, PHASE2 · active not recruiting
NCT02919449 — Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab · Phase 1 · terminated
NCT02923466 — Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03171493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vyriad, Inc.
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03171493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing